Mid-Size Japanese Device Makers Shift Market Focus To China
This article was originally published in PharmAsia News
Medium-sized makers of medical devices in Japan are shifting their focus to China and its larger market as a solution to their shrinking domestic market.
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.